Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 182 | 306 | 515 | 435 | 491 |
| Gross Profit | 182 | 306 | 515 | 435 | 491 |
| Operating Expenses | 2,137 | 2,149 | 3,671 | 3,143 | 2,784 |
| Operating Income | -1,955 | -1,843 | -3,156 | -2,707 | -2,294 |
| Interest Expense | 28 | 1,248 | 345 | 8 | 0 |
| Other Income | 15 | -26 | -4 | 24 | 55 |
| Pre-tax Income | -1,968 | -3,117 | -3,504 | -2,691 | -2,239 |
| Net Income Continuous | -1,968 | -3,117 | -3,504 | -2,691 | -2,239 |
| Minority Interests | N/A | 0 | -1 | -1 | -7 |
| Net Income | $-1,968 | $-3,117 | $-3,503 | $-2,690 | $-2,232 |
| EPS Basic Total Ops | -3.35 | -8.21 | -11.48 | -13.04 | -14.69 |
| EPS Basic Continuous Ops | -3.35 | -8.20 | -11.36 | -13.07 | -14.76 |
| EPS Diluted Total Ops | -3.35 | -8.21 | -11.48 | -13.04 | -14.69 |
| EPS Diluted Continuous Ops | -3.35 | -8.20 | -11.36 | -13.07 | -14.76 |
| EPS Diluted Before Non-Recurring Items | -3.30 | -8.25 | -16.94 | N/A | N/A |
| EBITDA(a) | $-1,930 | $-672 | $-3,156 | $-2,707 | $-2,294 |